Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen

Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "sell" rating in a research report issued on Saturday.Several other research analysts have also recently weighed in on IKT. Cantor Fitzgerald raised Inhibikase Therapeutics to a "strong-buy" rating in a research note on Thursday, December 11th. Zacks Research upgraded shares of Inhibikase Therapeutics to a "hold" rating in a research report on Tuesday, December 2nd. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday, December 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Inhibikase Therapeutics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Inhibikase Therapeutics currently has an average rating of "Moderate Buy".Read Our Latest Stock Report on IKTInhibikase Therapeutics Stock Up 21.2%Inhibikase Therapeutics stock opened at $2.00 on Friday. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $3.49. The company has a market capitalization of $150.36 million, a PE ratio of -5.13 and a beta of 0.88. The company has a 50 day moving average of $1.56. Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter. Inhibikase Therapeutics Company Profile (Get Free Report)Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.Featured StoriesFive stocks we like better than Inhibikase TherapeuticsDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Do you know what Amazon is planning for January 1?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Inhibikase Therapeutics Right Now?Before you consider Inhibikase Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here